Free Trial

Alkermes (ALKS) Stock Price, News & Analysis

Alkermes logo
$30.05 -0.48 (-1.57%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$30.04 0.00 (-0.02%)
As of 05/22/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Alkermes Stock (NASDAQ:ALKS)

Key Stats

Today's Range
$30.04
$30.57
50-Day Range
$26.59
$34.79
52-Week Range
$22.90
$36.45
Volume
694,655 shs
Average Volume
1.76 million shs
Market Capitalization
$4.96 billion
P/E Ratio
13.85
Dividend Yield
N/A
Price Target
$38.33
Consensus Rating
Moderate Buy

Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

ALKS MarketRank™: 

Alkermes scored higher than 93% of companies evaluated by MarketBeat, and ranked 76th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Alkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Alkermes has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Alkermes' stock forecast and price target.
  • Earnings Growth

    Earnings for Alkermes are expected to grow by 4.58% in the coming year, from $1.31 to $1.37 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Alkermes is 13.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Alkermes is 13.85, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.75.

  • Price to Earnings Growth Ratio

    Alkermes has a PEG Ratio of 2.20. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Alkermes has a P/B Ratio of 3.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Alkermes' valuation and earnings.
  • Percentage of Shares Shorted

    7.74% of the outstanding shares of Alkermes have been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Alkermes has recently increased by 3.32%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Alkermes does not currently pay a dividend.

  • Dividend Growth

    Alkermes does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.74% of the outstanding shares of Alkermes have been sold short.
  • Short Interest Ratio / Days to Cover

    Alkermes has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Alkermes has recently increased by 3.32%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Alkermes has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Alkermes this week, compared to 7 articles on an average week.
  • Search Interest

    1 people have searched for ALKS on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Alkermes insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.40% of the stock of Alkermes is held by insiders.

  • Percentage Held by Institutions

    95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Alkermes' insider trading history.
Receive ALKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter.

ALKS Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Headlines

ALKS Stock Analysis - Frequently Asked Questions

Alkermes' stock was trading at $28.76 on January 1st, 2025. Since then, ALKS shares have increased by 4.5% and is now trading at $30.05.
View the best growth stocks for 2025 here
.

Alkermes plc (NASDAQ:ALKS) released its quarterly earnings data on Thursday, May, 1st. The company reported $0.13 EPS for the quarter, missing analysts' consensus estimates of $0.32 by $0.19. Alkermes's quarterly revenue was down 12.6% on a year-over-year basis.
Read the conference call transcript
.

Alkermes' board authorized a stock repurchase program on Thursday, February 15th 2024, which allows the company to buy back $400,000,000 in outstanding shares, according to EventVestor. This means that the company could purchase up to 8.2% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's leadership believes its stock is undervalued.

Alkermes subsidiaries include Rodin Therapeutics.

Top institutional shareholders of Alkermes include Vanguard Group Inc. (11.05%), Price T Rowe Associates Inc. MD (7.15%), JPMorgan Chase & Co. (3.17%) and Baker BROS. Advisors LP (2.72%). Insiders that own company stock include Christian Todd Nichols, Craig C Hopkinson, Cato T Laurencin and Nancy Wysenski.
View institutional ownership trends
.

Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alkermes investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/01/2025
Today
5/23/2025
Next Earnings (Estimated)
7/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ALKS
Employees
2,280
Year Founded
1987

Price Target and Rating

Average Stock Price Target
$38.33
High Stock Price Target
$52.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+27.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
13.85
Forward P/E Ratio
22.94
P/E Growth
2.2
Net Income
$367.07 million
Pretax Margin
28.49%

Debt

Sales & Book Value

Annual Sales
$1.51 billion
Cash Flow
$2.26 per share
Price / Cash Flow
13.32
Book Value
$9.05 per share
Price / Book
3.32

Miscellaneous

Free Float
154,662,000
Market Cap
$4.96 billion
Optionable
Optionable
Beta
0.51

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ALKS) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners